Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report report published on Tuesday,Benzinga reports. The firm currently has a $7.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $3.12 on Tuesday. The business’s fifty day moving average is $3.26 and its 200-day moving average is $2.99. The stock has a market cap of $100.40 million, a PE ratio of -8.00 and a beta of 0.84. Anixa Biosciences has a 1 year low of $2.14 and a 1 year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Friday, September 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. Equities research analysts predict that Anixa Biosciences will post -0.42 earnings per share for the current year.

Institutional Trading of Anixa Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of ANIX. Tyler Stone Wealth Management lifted its stake in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the last quarter. International Assets Investment Management LLC grew its position in shares of Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Concorde Asset Management LLC acquired a new stake in Anixa Biosciences in the 2nd quarter valued at approximately $31,000. Nations Financial Group Inc. IA ADV raised its stake in Anixa Biosciences by 50.0% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after purchasing an additional 7,500 shares during the last quarter. Finally, Virtu Financial LLC raised its position in shares of Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares during the last quarter. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.